Daily Stock Analysis, CELGZ, Celgene Corp, priceseries

Celgene Corp. Daily Stock Analysis
Stock Information
Open
1.15
Close
1.16
High
1.16
Low
1.15
Previous Close
1.20
Daily Price Gain
-0.04
YTD High
1.61
YTD High Date
Jun 8, 2016
YTD Low
0.99
YTD Low Date
Oct 4, 2016
YTD Price Change
-0.12
YTD Gain
-9.45%
52 Week High
1.90
52 Week High Date
Oct 30, 2015
52 Week Low
0.92
52 Week Low Date
Dec 14, 2015
52 Week Price Change
-0.43
52 Week Gain
-27.11%
Company Information
Stock Symbol
CELGZ
Exchange
NasdaqGM
Company URL
http://www.celgene.com
Company Phone
(908)673-9000
CEO
Mark J. Alles
Headquarters
New Jersey
Business Address
86 MORRIS AVENUE, SUMMIT, NJ 07901
Sector
Healthcare
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000816284
About

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly...

Description

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet's disease, atopic dermatitis, and ulcerative colitis. The company's products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; and Nurix, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.